WVU jumps on CRO bandwagon; PSI signs on for Synta's Phase III;

> Following a trend among major research universities, West Virginia University is launching a CRO of its own. Article

> PSI CRO has signed on to conduct Phase III trials of ganetespib, a lung cancer drug under development by Synta Pharmaceuticals. Release

> WuXi PharmaTech ($WX) is expanding its deal with Open Monoclonal Technology to use its transgenic rat models for drug development. Story

> Marken has opened a new GMP-compliant facility in Beijing, expanding its clinical trial supply capabilities. News

> Pharma supplier Ashland is expanding its contract manufacturing business in Delaware to meet client demand. Report

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.